RECRUITING

Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

Talk to us

Conditions

Alcohol Use DisorderSubstance Abuse DisorderAlcohol

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to examine the effects of Low-Intensity Focused Ultrasound (LIFU) on brain activity in patients with alcohol use disorder.

Official Title

Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

Quick Facts

Study Start:2025-01-07
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06518785

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female ≥ 18 years of age.
  2. 2. Documentation of an AUD diagnosis per DSM-5 criteria as evidenced by problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the DSM-5 criteria, occurring within a 12-month period.
  3. 3. Be willing to undergo a brain MRI and follow study protocol.
  1. 1. Pregnant or breastfeeding.
  2. 2. Presence of a condition or abnormality that would compromise the safety of the patient or the quality of the data.
  3. 3. Non-English speaking.
  4. 4. Other investigational AUD treatments.
  5. 5. Primary psychosis, Bipolar I, or severe personality disorder.
  6. 6. Active suicidality or history of suicide attempt in the past 5 years.
  7. 7. Cognitive impairment (MoCA \<24)
  8. 8. Significant medical or neurological disease, or life expectancy \<12 mos.
  9. 9. Significant brain abnormality on brain imaging.
  10. 10. Any MRI exclusion criteria.

Contacts and Locations

Study Contact

Catherine Borror, BS, CCRP
CONTACT
415-514-6551
TN2Lab@ucsf.edu
Sierra Brandts, BS
CONTACT
415-514-6551
TN2Lab@ucsf.edu

Principal Investigator

Khaled Moussawi, MD, PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Khaled Moussawi, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-07
Study Completion Date2027-09

Study Record Updates

Study Start Date2025-01-07
Study Completion Date2027-09

Terms related to this study

Keywords Provided by Researchers

  • Substance Abuse Disorder
  • Alcohol

Additional Relevant MeSH Terms

  • Alcohol Use Disorder